Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Med Chem ; 67(11): 9465-9484, 2024 Jun 13.
Artículo en Inglés | MEDLINE | ID: mdl-38753983

RESUMEN

Clostridioides difficile (C. difficile) is one of the leading causes of healthcare-associated infections worldwide. The increasing incidence of strains resistant to currently available therapies highlights the need for alternative treatment options with a novel mode of action. Oxazolidinones that are connected to a quinolone moiety with a pyrrolidine linker, such as compound 1, are reported to exhibit potent broadspectrum antibacterial activity. In an effort to optimize this class of compounds for the treatment of C. difficile infection (CDI), we have identified cadazolid (9), a first-in-class quinoxolidinone antibiotic, which is a potent inhibitor of C. difficile protein synthesis. In order to achieve narrow-spectrum coverage of clinically most relevant strains without affecting the gut microbiota, an emphasis was placed on abolishing activity against commensals of the intestinal microbiome while retaining good coverage of pathogenic C. difficile, including hypervirulent and epidemic strains.


Asunto(s)
Antibacterianos , Clostridioides difficile , Infecciones por Clostridium , Pruebas de Sensibilidad Microbiana , Relación Estructura-Actividad , Antibacterianos/farmacología , Antibacterianos/química , Antibacterianos/uso terapéutico , Antibacterianos/síntesis química , Clostridioides difficile/efectos de los fármacos , Infecciones por Clostridium/tratamiento farmacológico , Animales , Humanos , Descubrimiento de Drogas , Microbioma Gastrointestinal/efectos de los fármacos , Ratones , Oxazolidinonas
2.
Proc Am Control Conf ; 2023: 1576-1583, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37521902

RESUMEN

Modern control theory provides us with a spectrum of methods for studying the interconnection of dynamic systems using input-output properties of the interconnected subsystems. Perhaps the most advanced framework for such input-output analysis is the use of Integral Quadratic Constraints (IQCs), which considers the interconnection of a nominal linear system with an unmodelled nonlinear or uncertain subsystem with known input-output properties. Although these methods are widely used for Ordinary Differential Equations (ODEs), there have been fewer attempts to extend IQCs to infinite-dimensional systems. In this paper, we present an IQC-based framework for Partial Differential Equations (PDEs) and Delay Differential Equations (DDEs). First, we introduce infinite-dimensional signal spaces, operators, and feedback interconnections. Next, in the main result, we propose a formulation of hard IQC-based input-output stability conditions, allowing for infinite-dimensional multipliers. We then show how to test hard IQC conditions with infinite-dimensional multipliers on a nominal linear PDE or DDE system via the Partial Integral Equation (PIE) state-space representation using a sufficient version of the Kalman-Yakubovich-Popov lemma (KYP). The results are then illustrated using four example problems with uncertainty and nonlinearity.

3.
Water Sci Technol ; 84(9): 2353-2365, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34810316

RESUMEN

Grey-box models, which combine the explanatory power of first-principle models with the ability to detect subtle patterns from data, are gaining increasing attention in wastewater sectors. Intuitive, simple structured but fit-for-purpose grey-box models that capture time-varying dynamics by adaptively estimating parameters are desired for process optimization and control. As an example, this study presents the identification of such a grey-box model structure and its further use by an extended Kalman filter (EKF), for the estimation of the nitrification capacity and ammonia concentrations of a typical Modified Ludzack-Ettinger (MLE) process. The EKF was implemented and evaluated in real time by interfacing Python with SUMO (Dynamita™), a widely used commercial process simulator. The EKF was able to accurately estimate the ammonia concentrations in multiple tanks when given only the concentration in one of them. In addition, the nitrification capacity of the system could be tracked in real time by the EKF, which provides intuitive information for facility managers and operators to monitor and operate the system. Finally, the realization of EKF is critical to the development of future advance control, for instance, model predictive control.


Asunto(s)
Amoníaco , Aguas Residuales
4.
J Med Chem ; 63(1): 66-87, 2020 01 09.
Artículo en Inglés | MEDLINE | ID: mdl-31804826

RESUMEN

UDP-3-O-((R)-3-hydroxymyristoyl)-N-glucosamine deacetylase (LpxC) is as an attractive target for the discovery and development of novel antibacterial drugs to address the critical medical need created by multidrug resistant Gram-negative bacteria. By using a scaffold hopping approach on a known family of methylsulfone hydroxamate LpxC inhibitors, several hit series eliciting potent antibacterial activities against Enterobacteriaceae and Pseudomonas aeruginosa were identified. Subsequent hit-to-lead optimization, using cocrystal structures of inhibitors bound to Pseudomonas aeruginosa LpxC as guides, resulted in the discovery of multiple chemical series based on (i) isoindolin-1-ones, (ii) 4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-ones, and (iii) 1,2-dihydro-3H-pyrrolo[1,2-c]imidazole-3-ones. Synthetic methods, antibacterial activities and relative binding affinities, as well as physicochemical properties that allowed compound prioritization are presented. Finally, in vivo properties of lead molecules which belong to the most promising pyrrolo-imidazolone series, such as 18d, are discussed.


Asunto(s)
Amidohidrolasas/antagonistas & inhibidores , Antibacterianos/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Infecciones por Escherichia coli/tratamiento farmacológico , Bacterias Gramnegativas/efectos de los fármacos , Ácidos Hidroxámicos/uso terapéutico , Animales , Antibacterianos/síntesis química , Antibacterianos/farmacocinética , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacocinética , Escherichia coli/efectos de los fármacos , Femenino , Ácidos Hidroxámicos/síntesis química , Ácidos Hidroxámicos/farmacocinética , Klebsiella pneumoniae/efectos de los fármacos , Ratones Endogámicos ICR , Pruebas de Sensibilidad Microbiana , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/enzimología , Pirroles/síntesis química , Pirroles/farmacocinética , Pirroles/uso terapéutico
5.
J Med Chem ; 63(1): 88-102, 2020 01 09.
Artículo en Inglés | MEDLINE | ID: mdl-31804829

RESUMEN

LpxC inhibitors were optimized starting from lead compounds with limited efficacy and solubility and with the goal to provide new options for the treatment of serious infections caused by Gram-negative pathogens in hospital settings. To enable the development of an aqueous formulation for intravenous administration of the drug at high dose, improvements in both solubility and antibacterial activity in vivo were prioritized early on. This lead optimization program resulted in the discovery of compounds such as 13 and 30, which exhibited high solubility and potent efficacy against Gram-negative pathogens in animal infection models.


Asunto(s)
Amidohidrolasas/antagonistas & inhibidores , Antibacterianos/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Infecciones por Escherichia coli/tratamiento farmacológico , Ácidos Hidroxámicos/uso terapéutico , Administración Intravenosa , Animales , Antibacterianos/administración & dosificación , Antibacterianos/síntesis química , Antibacterianos/farmacocinética , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacocinética , Bacterias Gramnegativas/efectos de los fármacos , Hepatocitos/metabolismo , Ácidos Hidroxámicos/administración & dosificación , Ácidos Hidroxámicos/síntesis química , Ácidos Hidroxámicos/farmacocinética , Ratones , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Ratas , Solubilidad
6.
IEEE ASME Trans Mechatron ; 23(4): 1532-1542, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30595643

RESUMEN

Optical tweezers have enabled important insights into intracellular transport through the investigation of motor proteins, with their ability to manipulate particles at the microscale, affording femto newton force resolution. Its use to realize a constant force clamp has enabled vital insights into the behavior of motor proteins under different load conditions. However, the varying nature of disturbances and the effect of thermal noise pose key challenges to force regulation. Furthermore, often the main aim of many studies is to determine the motion of the motor and the statistics related to the motion, which can be at odds with the force regulation objective. In this article, we propose a mixed objective H 2 /H ∞ optimization framework using a model-based design, that achieves the dual goals of force regulation and real time motion estimation with quantifiable guarantees. Here, we minimize the H ∞ norm for the force regulation and error in step estimation while maintaining the H 2 norm of the noise on step estimate within user specified bounds. We demonstrate the efficacy of the framework through extensive simulations and an experimental implementation using an optical tweezer setup with live samples of the motor protein 'kinesin'; where regulation of forces below 1 piconewton with errors below 10% is obtained while simultaneously providing real time estimates of motor motion.

7.
J Med Chem ; 60(9): 3755-3775, 2017 05 11.
Artículo en Inglés | MEDLINE | ID: mdl-28406299

RESUMEN

Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the minimal ethyl urea binding motif led to the identification of isoquinoline ethyl urea 13 as a promising starting point for fragment evolution. The optimization was guided by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating in the discovery of unprecedented substituents able to interact with conserved residues within the ATP-binding site. A detailed characterization of the lead compound highlighted the potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the identification of a suitable prodrug concept. Eventually, hERG K-channel block was identified as the main limitation of this chemical series, and efforts toward its minimization are reported.


Asunto(s)
Antibacterianos/farmacología , Isoquinolinas/farmacología , Animales , Antibacterianos/química , Área Bajo la Curva , Descubrimiento de Drogas , Bacterias Gramnegativas/efectos de los fármacos , Semivida , Enlace de Hidrógeno , Isoquinolinas/química , Isoquinolinas/farmacocinética , Isoquinolinas/uso terapéutico , Pruebas de Sensibilidad Microbiana , Canales de Potasio/efectos de los fármacos , Ratas , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/microbiología , Solubilidad , Urea/química
8.
J Med Chem ; 60(9): 3776-3794, 2017 05 11.
Artículo en Inglés | MEDLINE | ID: mdl-28406300

RESUMEN

There is an urgent unmet medical need for novel antibiotics that are effective against a broad range of bacterial species, especially multidrug resistant ones. Tetrahydropyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent activity against Gram-positive pathogens and no target-mediated cross-resistance with fluoroquinolones. We report our research efforts aimed at expanding the antibacterial spectrum of this class of molecules toward difficult-to-treat Gram-negative pathogens. Physicochemical properties (polarity and basicity) were considered to guide the design process. Dibasic tetrahydropyran-based compounds such as 6 and 21 are potent inhibitors of both DNA gyrase and topoisomerase IV, displaying antibacterial activities against Gram-positive and Gram-negative pathogens (Staphylococcus aureus, Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii). Compounds 6 and 21 are efficacious in clinically relevant murine infection models.


Asunto(s)
Antibacterianos/farmacología , Bacterias Gramnegativas/efectos de los fármacos , Piranos/farmacología , Inhibidores de Topoisomerasa/síntesis química , Inhibidores de Topoisomerasa/farmacología , Animales , Antibacterianos/efectos adversos , Antibacterianos/síntesis química , Cobayas , Humanos , Pruebas de Sensibilidad Microbiana , Miocitos Cardíacos/efectos de los fármacos , Piranos/efectos adversos , Piranos/síntesis química , Inhibidores de Topoisomerasa/efectos adversos
9.
Antimicrob Agents Chemother ; 60(1): 628-31, 2016 01.
Artículo en Inglés | MEDLINE | ID: mdl-26503650

RESUMEN

The promotion of colonization with vancomycin-resistant enterococci (VRE) is one potential side effect during treatment of Clostridium difficile-associated diarrhea (CDAD), resulting from disturbances in gut microbiota. Cadazolid (CDZ) is an investigational antibiotic with potent in vitro activity against C. difficile and against VRE and is currently in clinical development for the treatment of CDAD. We report that CDZ treatment did not lead to intestinal VRE overgrowth in mice.


Asunto(s)
Antibacterianos/efectos adversos , Clostridioides difficile/efectos de los fármacos , Diarrea/tratamiento farmacológico , Enterocolitis Seudomembranosa/tratamiento farmacológico , Oxazolidinonas/farmacología , Vancomicina/efectos adversos , Aminoglicósidos/farmacología , Animales , Antibacterianos/administración & dosificación , Clostridioides difficile/crecimiento & desarrollo , Clostridioides difficile/patogenicidad , Recuento de Colonia Microbiana , Diarrea/etiología , Diarrea/microbiología , Diarrea/patología , Enterocolitis Seudomembranosa/etiología , Enterocolitis Seudomembranosa/microbiología , Enterocolitis Seudomembranosa/patología , Fidaxomicina , Intestinos/efectos de los fármacos , Intestinos/microbiología , Intestinos/patología , Metronidazol/farmacología , Ratones , Pruebas de Sensibilidad Microbiana , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/microbiología , Infecciones Estreptocócicas/patología , Resultado del Tratamiento , Vancomicina/administración & dosificación , Resistencia a la Vancomicina , Enterococos Resistentes a la Vancomicina/efectos de los fármacos , Enterococos Resistentes a la Vancomicina/crecimiento & desarrollo , Enterococos Resistentes a la Vancomicina/patogenicidad
10.
J Med Chem ; 58(2): 927-42, 2015 Jan 22.
Artículo en Inglés | MEDLINE | ID: mdl-25494934

RESUMEN

Novel antibacterial drugs that are effective against infections caused by multidrug resistant pathogens are urgently needed. In a previous report, we have shown that tetrahydropyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. During the course of our optimization program, lead compound 5 was deprioritized due to adverse findings in cardiovascular safety studies. In the effort of mitigating these findings and optimizing further the pharmacological profile of this class of compounds, we have identified a subseries of tetrahydropyran-based molecules that are potent DNA gyrase and topoisomerase IV inhibitors and display excellent antibacterial activity against Gram positive pathogens, including clinically relevant resistant isolates. One representative of this class, compound 32d, elicited only weak inhibition of hERG K(+) channels and hNaV1.5 Na(+) channels, and no effects were observed on cardiovascular parameters in anesthetized guinea pigs. In vivo efficacy in animal infection models has been demonstrated against Staphylococcus aureus and Streptococcus pneumoniae strains.


Asunto(s)
Antibacterianos/síntesis química , Bacterias Grampositivas/efectos de los fármacos , Piranos/síntesis química , Inhibidores de Topoisomerasa II/síntesis química , Animales , Antibacterianos/farmacología , Cobayas , Hemodinámica/efectos de los fármacos , Humanos , Masculino , Ratones , Pruebas de Sensibilidad Microbiana , Piranos/farmacología , Ratas , Ratas Wistar , Relación Estructura-Actividad , Inhibidores de Topoisomerasa II/farmacología
11.
Antimicrob Agents Chemother ; 58(2): 892-900, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24277020

RESUMEN

Clostridium difficile is a leading cause of health care-associated diarrhea with significant morbidity and mortality, and new options for the treatment of C. difficile-associated diarrhea (CDAD) are needed. Cadazolid is a new oxazolidinone-type antibiotic that is currently in clinical development for treatment of CDAD. Here, we report the in vitro and in vivo antibacterial evaluation of cadazolid against C. difficile. Cadazolid showed potent in vitro activity against C. difficile with a MIC range of 0.125 to 0.5 µg/ml, including strains resistant to linezolid and fluoroquinolones. In time-kill kinetics experiments, cadazolid showed a bactericidal effect against C. difficile isolates, with >99.9% killing in 24 h, and was more bactericidal than vancomycin. In contrast to metronidazole and vancomycin, cadazolid strongly inhibited de novo toxin A and B formation in stationary-phase cultures of toxigenic C. difficile. Cadazolid also inhibited C. difficile spore formation substantially at growth-inhibitory concentrations. In the hamster and mouse models for CDAD, cadazolid was active, conferring full protection from diarrhea and death with a potency similar to that of vancomycin. These findings support further investigations of cadazolid for the treatment of CDAD.


Asunto(s)
Antibacterianos/farmacología , Clostridioides difficile/efectos de los fármacos , Infecciones por Clostridium/tratamiento farmacológico , Enterocolitis Seudomembranosa/tratamiento farmacológico , Oxazolidinonas/farmacología , Esporas Bacterianas/efectos de los fármacos , Acetamidas/farmacología , Animales , Proteínas Bacterianas/antagonistas & inhibidores , Proteínas Bacterianas/biosíntesis , Toxinas Bacterianas/antagonistas & inhibidores , Toxinas Bacterianas/biosíntesis , Clostridioides difficile/crecimiento & desarrollo , Clostridioides difficile/metabolismo , Infecciones por Clostridium/microbiología , Infecciones por Clostridium/mortalidad , Cricetinae , Enterocolitis Seudomembranosa/microbiología , Enterocolitis Seudomembranosa/mortalidad , Enterotoxinas/antagonistas & inhibidores , Enterotoxinas/biosíntesis , Femenino , Fluoroquinolonas/farmacología , Humanos , Linezolid , Masculino , Metronidazol/farmacología , Ratones , Ratones Endogámicos C57BL , Pruebas de Sensibilidad Microbiana , Esporas Bacterianas/crecimiento & desarrollo , Análisis de Supervivencia , Vancomicina/farmacología
12.
J Med Chem ; 56(18): 7396-415, 2013 Sep 26.
Artículo en Inglés | MEDLINE | ID: mdl-23968485

RESUMEN

There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase-topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K(+) channel block. On the other hand, analog 49e displayed lower hERG K(+) channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.


Asunto(s)
Antibacterianos/síntesis química , Antibacterianos/farmacología , ADN-Topoisomerasas/metabolismo , Diseño de Fármacos , Bacterias Grampositivas/efectos de los fármacos , Piranos/síntesis química , Piranos/farmacología , Animales , Antibacterianos/metabolismo , Antibacterianos/farmacocinética , Técnicas de Química Sintética , Girasa de ADN/química , Girasa de ADN/metabolismo , Topoisomerasa de ADN IV/antagonistas & inhibidores , Topoisomerasa de ADN IV/química , Topoisomerasa de ADN IV/metabolismo , ADN-Topoisomerasas/química , Femenino , Bacterias Grampositivas/enzimología , Humanos , Concentración 50 Inhibidora , Ratones , Simulación del Acoplamiento Molecular , Conformación Proteica , Piranos/metabolismo , Piranos/farmacocinética , Ratas , Relación Estructura-Actividad , Inhibidores de Topoisomerasa II , Inhibidores de Topoisomerasa/síntesis química , Inhibidores de Topoisomerasa/metabolismo , Inhibidores de Topoisomerasa/farmacocinética , Inhibidores de Topoisomerasa/farmacología
13.
Bioorg Med Chem Lett ; 22(21): 6705-11, 2012 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-23006603

RESUMEN

A series of 2-amino-[1,8]-naphthyridine-3-carboxamides (ANCs) with potent inhibition of bacterial NAD(+)-dependent DNA ligases (LigAs) evolved from a 2,4-diaminopteridine derivative discovered by HTS. The design was guided by several highly resolved X-ray structures of our inhibitors in complex with either Streptococcus pneumoniae or Escherichia coli LigA. The structure-activity-relationship based on the ANC scaffold is discussed. The in-depth characterization of 2-amino-6-bromo-7-(trifluoromethyl)-[1,8]-naphthyridine-3-carboxamide, which displayed promising in vitro (MIC Staphylococcus aureus 1 mg/L) and in vivo anti-staphylococcal activity, is presented.


Asunto(s)
Antibacterianos/síntesis química , Antibacterianos/farmacología , ADN Ligasas/antagonistas & inhibidores , Diseño de Fármacos , Staphylococcus/efectos de los fármacos , Animales , Antibacterianos/química , Antibacterianos/uso terapéutico , Cristalografía por Rayos X , ADN Bacteriano/antagonistas & inhibidores , Concentración 50 Inhibidora , Ratones , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Ratas , Infecciones Estafilocócicas/tratamiento farmacológico , Relación Estructura-Actividad
14.
J Clin Microbiol ; 44(10): 3760-7, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17021106

RESUMEN

With fluorescently labeled PNA (peptide nucleic acid) probes targeting 16S rRNA, we established a 3-h fluorescence in situ hybridization (FISH) procedure for specific visualization of members of the Mycobacterium tuberculosis complex, M. leprae, M. avium, and M. kansasii. Probe specificity was tested against a panel of 25 Mycobacterium spp. and 10 gram-positive organisms. After validation, probes were used to identify 52 mycobacterial culture isolates. Results were compared to conventional genotypic identification with amplification-based methods. All isolates (M. tuberculosis complex, n = 24; M. avium, n = 7; M. kansasii, n = 1) were correctly identified by FISH. In addition, the technique was used successfully for visualization of mycobacteria in biopsies from infected humans or animals. In conclusion, PNA-FISH is a fast and accurate tool for species-specific identification of culture-grown mycobacteria and for direct visualization of these organisms in tissue sections. It may be used successfully for both research and clinical microbiology.


Asunto(s)
Hibridación Fluorescente in Situ/métodos , Infecciones por Mycobacterium/diagnóstico , Mycobacterium/clasificación , Ácidos Nucleicos de Péptidos , Humanos , Mycobacterium/aislamiento & purificación , Infecciones por Mycobacterium/microbiología , Sondas de Ácido Nucleico , Sensibilidad y Especificidad
15.
Eur J Immunol ; 36(3): 631-47, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16479545

RESUMEN

A potent Th1 immune response is critical to the control of tuberculosis. The impact of an additive Th2 response on the course of disease has so far been insufficiently characterized, despite increased morbidity after co-infection with Mycobacterium tuberculosis and Th2-eliciting helminths and possible involvement of Th2 polarization in reactivation of latent tuberculosis. Here, we describe the gene expression profile of murine bone marrow-derived macrophages alternatively activated by IL-4 in response to infection with M. tuberculosis. Comparison of transcriptional profiles of infected IL-4- and IFN-gamma-activated macrophages revealed delayed and partially diminished responses to intracellular bacteria in alternatively activated macrophages, characterized by reduced exposure to nitrosative stress and increased iron availability, respectively. Alternative activation of host macrophages correlated with elevated expression of the M. tuberculosis iron storage protein bacterioferritin as well as reduced expression of the mycobactin synthesis genes mbtI and mbtJ. The extracellular matrix-remodeling enzyme matrix metalloproteinase (MMP)-12 was induced in alternatively activated macrophages in vitro, and MMP-12-expressing macrophages were abundant at late, but not early, stages of tuberculosis in murine lungs. Our findings emphasize that alternative activation deprives macrophages of control mechanisms that limit mycobacterial growth in vivo, thus supporting intracellular persistence of M. tuberculosis.


Asunto(s)
Células de la Médula Ósea/inmunología , Regulación de la Expresión Génica/inmunología , Activación de Macrófagos/inmunología , Macrófagos/inmunología , Mycobacterium tuberculosis/inmunología , Tuberculosis Pulmonar/inmunología , Animales , Antineoplásicos/farmacología , Proteínas Bacterianas/inmunología , Células de la Médula Ósea/microbiología , Células de la Médula Ósea/patología , Regulación de la Expresión Génica/efectos de los fármacos , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Regulación Bacteriana de la Expresión Génica/genética , Regulación Bacteriana de la Expresión Génica/inmunología , Helmintiasis/inmunología , Helmintiasis/patología , Interferón gamma/farmacología , Interleucina-4/farmacología , Hierro/inmunología , Pulmón/inmunología , Pulmón/microbiología , Pulmón/patología , Activación de Macrófagos/efectos de los fármacos , Macrófagos/microbiología , Macrófagos/patología , Metaloproteinasa 12 de la Matriz , Metaloendopeptidasas/inmunología , Ratones , Mycobacterium tuberculosis/genética , Oxazoles/inmunología , Células TH1/inmunología , Células Th2/inmunología , Tuberculosis Pulmonar/genética , Tuberculosis Pulmonar/patología
16.
J Clin Invest ; 115(9): 2472-9, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16110326

RESUMEN

The tuberculosis vaccine Mycobacterium bovis bacille Calmette-Guérin (BCG) was equipped with the membrane-perforating listeriolysin (Hly) of Listeria monocytogenes, which was shown to improve protection against Mycobacterium tuberculosis. Following aerosol challenge, the Hly-secreting recombinant BCG (hly+ rBCG) vaccine was shown to protect significantly better against aerosol infection with M. tuberculosis than did the parental BCG strain. The isogenic, urease C-deficient hly+ rBCG (DeltaureC hly+ rBCG) vaccine, providing an intraphagosomal pH closer to the acidic pH optimum for Hly activity, exhibited still higher vaccine efficacy than parental BCG. DeltaureC hly+ rBCG also induced profound protection against a member of the M. tuberculosis Beijing/W genotype family while parental BCG failed to do so consistently. Hly not only promoted antigen translocation into the cytoplasm but also apoptosis of infected macrophages. We concluded that superior vaccine efficacy of DeltaureC hly+ rBCG as compared with parental BCG is primarily based on improved cross-priming, which causes enhanced T cell-mediated immunity.


Asunto(s)
Vacuna BCG , Toxinas Bacterianas/metabolismo , Proteínas de Choque Térmico/metabolismo , Listeria monocytogenes/metabolismo , Tuberculosis/prevención & control , Adulto , Animales , Apoptosis , Proteínas Bacterianas/genética , Proteínas Bacterianas/inmunología , Células Cultivadas , Niño , Proteínas Hemolisinas , Humanos , Concentración de Iones de Hidrógeno , Listeria monocytogenes/inmunología , Macrófagos/citología , Macrófagos/metabolismo , Ratones , Ratones SCID , Mycobacterium tuberculosis/inmunología , Mycobacterium tuberculosis/metabolismo , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/uso terapéutico , Tasa de Supervivencia , Vacunas Sintéticas
17.
J Pathol ; 205(5): 633-40, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15776475

RESUMEN

The diagnosis of mycobacterial infection depends on the Ziehl-Neelsen (ZN) stain, which detects mycobacteria because of their characteristic acid-fast cell wall composition and structure. The histological diagnosis of tuberculosis (TB) comprises various aspects: (1) sensitive detection of mycobacteria; (2) precise localization of mycobacteria in the context of granulomatous lesions; (3) 'staging' of disease according to mycobacterial spread and granulomatous tissue integrity. Thus, detection of minute numbers of acid-fast bacteria in tissue specimens is critical. The conventional ZN stain fails to identify mycobacteria in numbers less than 10(4) per ml. Hence many infections evade diagnosis. PCR is highly sensitive, but allows neither localization within tissues nor staging of mycobacterial disease, and positive findings frequently do not correlate with disease. In this study, an anti-Mycobacterium bovis bacille Calmette-Guérin polyclonal antiserum (pAbBCG) was used to improve immunostaining, which was compared to the ZN stain in histological samples. Screening of tissue samples including lungs, pleural lesions, lymph nodes, bone marrow, and skin for mycobacterial infection revealed that pAbBCG staining detects infected macrophages harbouring intracellular mycobacteria or mycobacterial material as well as free mycobacteria that are present at low abundance and not detected by the ZN stain. The positive pAbBCG staining results were confirmed either by PCR analysis of microdissected stained tissue or by culture from tissue. This immunostaining approach allows precise localization of the pathogen in infected tissue.


Asunto(s)
Mycobacterium tuberculosis/aislamiento & purificación , Coloración y Etiquetado/métodos , Tuberculosis/diagnóstico , Sitios de Unión , Células Cultivadas , Humanos , Sueros Inmunes/inmunología , Hibridación Fluorescente in Situ/métodos , Microdisección/métodos , Mycobacterium bovis/inmunología , Reacción en Cadena de la Polimerasa/métodos , Sensibilidad y Especificidad , Tuberculosis/microbiología , Tuberculosis Pulmonar/diagnóstico , Tuberculosis Pulmonar/microbiología
18.
Tuberculosis (Edinb) ; 85(1-2): 29-38, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15687025

RESUMEN

The TB Vaccine Cluster project funded by the EU Fifth Framework programme aims to provide novel vaccines against tuberculosis that are suitable for evaluation in humans. This paper describes the studies of the protective efficacy of vaccines in a guinea pig aerosol-infection model of primary tuberculosis. The objective was to conduct comparative evaluations of vaccines that had previously demonstrated efficacy in other animal models. Groups of 6 guinea pigs were immunized with vaccines provided by the relevant EU Vaccine Cluster partners. Survival over 17 or 26 weeks was used as the principal measure of vaccine efficacy following aerosol challenge with H37Rv. Counts of mycobacteria in lungs and spleens, and histopathological changes in the lungs, were also used to provide evidence of protection. A total of 24 vaccines were evaluated in 4 experiments each of a different design. A heterologous prime-boost strategy of DNA and MVA, each expressing Ag85A and a fusion protein of ESAT-6 and Ag85B in adjuvant, protected the guinea pigs to the same extent as BCG. Genetically modified BCG vaccines and boosted BCG strategies also protected guinea pigs to the same extent as BCG but not statistically significantly better. A relatively high aerosol-challenge dose and evaluation over a protracted time post-challenge allowed superior protection over BCG to be demonstrated by BCG boosted with MVA and fowl pox vectors expressing Ag85A.


Asunto(s)
Modelos Animales de Enfermedad , Vacunas contra la Tuberculosis/uso terapéutico , Tuberculosis/prevención & control , Aerosoles , Animales , Vacuna BCG/uso terapéutico , Recuento de Colonia Microbiana/métodos , Evaluación Preclínica de Medicamentos/métodos , Unión Europea , Cobayas , Humanos , Pulmón/microbiología , Mycobacterium tuberculosis/inmunología , Mycobacterium tuberculosis/aislamiento & purificación , Bazo/microbiología , Análisis de Supervivencia , Tuberculosis/inmunología , Vacunas contra la Tuberculosis/inmunología , Tuberculosis Pulmonar/inmunología , Tuberculosis Pulmonar/prevención & control , Vacunación/métodos
20.
J Infect Dis ; 188(9): 1326-31, 2003 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-14593589

RESUMEN

Ziehl-Neelsen (ZN) staining is the key technique for diagnosis of mycobacterial infections; however, a high percentage of patients exhibit positive signs of tuberculosis, as indicated by pathology, culture of mycobacteria, and polymerase chain-reaction analysis, and yet show negative results on ZN staining. In this report we present evidence that such ZN-negative specimens represent Mycobacterium tuberculosis bacilli in a dormant state with distinct cell-wall alterations: the classical cell-wall composition-dependent ZN staining of M. tuberculosis in lung sections gradually discontinued with persistence of infection, both in mice and in human patients; in contrast, detection of mycobacteria by cell-wall composition-independent staining using a polyclonal anti-M. bovis Bacille-Calmette-Guérin serum continued with persistence of infection. These findings have important implications for diagnosis, as well as for both chemotherapy and development of vaccine strategies.'


Asunto(s)
Mycobacterium tuberculosis/ultraestructura , Colorantes de Rosanilina , Tuberculosis/microbiología , Animales , Vacuna BCG , Proteínas Bacterianas/metabolismo , Pared Celular/metabolismo , Femenino , Humanos , Inmunohistoquímica , Pulmón/microbiología , Masculino , Ratones , Ratones Endogámicos C57BL , Mycobacterium tuberculosis/metabolismo , Coloración y Etiquetado/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...